Skip to main content

Table 1 Patient characteristics, vaccination course and clinical outcome.

From: High Immune Response Rates and Decreased Frequencies of Regulatory T Cells in Metastatic Renal Cell Carcinoma Patients after Tumor Cell Vaccination

ID Prognostic scorea Therapy before study entry Site(s) of metastases 2.5 × 106 cells 10 × 106 cells 40 × 106 cells Site(s) of progression TTP (wks) Survival (wks)
MR-1 2 Lung, bone 4 1 Bone, brainb 7 31
MR-2 1 Cytokine,c G250d Lung, LN 4 4 2 Pleura,b boneb 23 79
MR-4 1 Cytokine, G250 Lung, LN, adrenal gland 4 4 2 Lung 35 68
MR-5 1 Cytokine Lung 4 4 2 LN,b adrenal glandb 7 76
MR-6 2 Bone 4 2 Bone 6 18
MR-7 1 LN, pleura, local recurrence 4 2 Pleura, liverb 28 84
MR-9 2 Cytokine Lung, pancreas 4 2 Pancreas, liverb 39 79
MR-10 0 Sorafenib Lung 4 4 2 Brainb 23 55
MR-11 2 G250 Lung, LN, spinal cord 4 4 SD (7)e 17f
MR-13 1 DC, multi-peptide vaccine Lung, LN, brain 4 4 2 Brain 33 104
MR-14 2 Multi-peptide vaccine Lung, LN, adrenal gland 4 4 2 LN 35 107
MR-15 1 Cytokine Lung, LN 4 4 2 SD (131)e 151 (alive)
  1. TTP time to progression; LN, lymph node; DC, dendritic cell; SD, stable disease.
  2. aPalmer score from 0 (very low risk) to 3 (high risk) based on performance status, number of metastatic sites and the time from first diagnosis to study entry (14).
  3. bNew metastases.
  4. cCytokine: IFN-α, IL-2, 5-fluorouracil.
  5. dG250: monoclonal antibody directed against carbonic anhydrase IX.
  6. eSD (7) and SD (131) indicate stable disease at wks 7 and 131, respectively.
  7. fDeath of patient MR-11, not related to therapy or disease.